Assistant Professor
Oncology
Dr. Igor A. Astsaturov, MD
|
|
Give Review
Igor Astsaturov works in the field of Oncology. He went to medical school at Russian State Medical University. He over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Igor Astsaturov is also published. He has 40 publications published. The lastest publication: "[A benign form of chronic lympholeukemia].' Doctor Igor A. Astsaturov, MD accepts Medicare payments and is listed with Medicare.gov.
Publications
- HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted DeLivery of Topoisomerase I Inhibitor to Tumors.
- Increased time from neoadjuvant chemoradiation to surgery is associated with higher pathologic complete response rates in esophageal Cancer.
- Phase I study of capecitabine combined with radioembolization using yttrium-90 resin microspheres (SIR-Spheres) in patients with advanced Cancer.
- Successful Imatinib Therapy for Neuroendocrine Carcinoma With Activating KIT Mutation: A Case Study.
- Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints.
- Molecular Pathways: Sterols and receptor signaling in Cancer.
- Aurora kinases in head and neck Cancer.
- DUSP6 regulates drug sensitivity by modulating DNA damage response.
- Network Analysis identifies an HSP90-central hub susceptible in ovarian cancer.
- Aurora A kinase (AURKA) in normal and pathological cell division.
- Targeting C4-Demethylating Genes in the Cholesterol Pathway Sensitizes Cancer Cells to EGF Receptor Inhibitors via Increased EGF Receptor Degradation.
- Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment.
- Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic Pancreatic adenocarcinoma.
- Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic coloRectal cancer.
- Significance of pathologic response to preoperative therapy in pancreatic Cancer.
- Defining venous involvement in borderline resectable pancreatic Cancer.
- Targeting EGFR resistance networks in head and neck Cancer.
- Selective Raf inhibition in Cancer therapy.
- Clinical application of EGFR inhibitors in head and neck squamous cell Cancer.
- Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100.
- Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in coloRectal cancer.
- Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-alpha2b: implications for Cancer vaccines.
- Primary Sjögren's syndrome and deficiency of ICA69.
- ICA69(null) nonobese diabetic mice develop diabetes, but resist disease acceleration by cyclophosphamide.
- T cells of multiple sclerosis patients target a common environmental peptide that causes encephalitis in mice.
- Type I diabetes and multiple sclerosis patients target islet plus central nervous system autoantigens; nonimmunized nonobese diabetic mice can develop autoimmune encep...
- Novel functional activities of anti-DNA autoantibodies from sera of patients with lymphoproliferative and autoimmune diseases.
- [A benign form of chronic lympholeukemia].
- The relevance of cytological studies and Ki-67 reactivity to the clinical course of chronic lymphocytic leukemia.
- [DNA-hydrolyzing antibodies in lymphoproliferative disorders].
- [Lymphocytoma of the spleen--a separate nosological form requiring a specific management procedure].
- Differential expression of B29 (CD79b) and mb-1 (CD79a) proteins in acute lymphoblastic leukaemia.
- [Errors in the diagnosis and therapy of chronic lympholeukemias].
- The emerging role of cetuximab in head and neck Cancer: a 2007 perspective.
- EGFR-targeting monoclonal antibodies in head and neck Cancer.
- Targeting epidermal growth factor receptor signaling in the treatment of head and neck Cancer.
- Mechanisms of tumor resistance to EGFR-targeted therapies.
- Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?
- Synthetic lethal screen of an EGFR-centered network to improve targeted therapies.
Schools
Moscow Medical Academy Named After Im Sechenov
Good Samar Hospital
Fox Chase Canc Center
Procedures Preformed
- Thoracentesis
Conditions Treated
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Personal Choice PPO
- Regional Pref Network EPO
- Regional Pref Network HMO
- Regional Pref Network HMO+
- Regional Pref Network POS+
- Regional Pref Network PPO
- Blue Card PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- Geisinger Health Plan
- Community Blue PPO
- Direct Access
- Horizon Blue Cross Blue Shield HMO
- Horizon Blue Cross Blue Shield POS
- Horizon Blue Cross Blue Shield PPO
- Choice Care PPO
- Keystone Health Plan East HMO
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- QualCare HMO
- QualCare PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Temple University Hospital -
Russian State Medical University
Hospital
-
Fox Chase Cancer Center-American Oncologic Hospital -
Temple University Hospital
Drug Facts
| NPI NUMBER | 1235314204 | |
| NPPES Provider LastName | ASTSATUROV | |
| NPPES Provider FirstName | IGOR | |
| NPPES Provider ZIPCode | 191112434 | |
| NPPES Provider State | PA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 94.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1235314204 |
| Last Name Of The Provider | ASTSATUROV |
| First Name Of The Provider | IGOR |
| View All |
Similar Doctors
|
|
Dr. Anthony J. Olszanski, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Frederick G. Dold, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lainie Martin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael A. Bookman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sujana Movva, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Diane M. Hershock, MD |
|
|
Dr. David L. Bajor, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brandon E. Kremer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Evan W. Alley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John H. Glick, MD
This Doctor is OpenDoctor Recommended.
|